Rationale and design of the AUGUST-AHF Study

Jingjing Zhang¹,², Yang Sun¹, Kehua Zhou³, Xiaoyu Zhang¹,², Ying Chen¹,², Jiayuan Hu¹,², Changming Zhong¹,², Yan Liu²* and Hongcai Shang²*

¹Beijing University of Chinese Medicine, Beijing, China; ²Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dangshimen Hospital, Beijing University of Chinese Medicine, Beijing, China; and ³Catholic Health System Internal Medicine Training Program, University at Buffalo, Buffalo, NY, USA

Abstract

Aims We aim to assess the effect of a lyophilized herbal injection on 90 day mortality and readmission rates in patients with acute heart failure (AHF).

Methods and results The AUGUST-AHF study is a multicentre, randomized, double-blind, placebo-controlled trial enrolling 1270 hospitalized patients for AHF. Patients are randomized to receive YiqiFumai lyophilized injection (5.2 g/day) or placebo for 10 days, in addition to standard therapy, using a 1:1 ratio via an interactive web response system. The primary endpoint is the 90 day all-cause mortality or AHF readmission rates. Secondary endpoints include 180 day all-cause mortality or heart failure readmission rates, length of hospital stay for the indexed AHF, 90 day cardiac-specific mortality rate, occurrence of worsening heart failure through Day 10, changes in the Minnesota Living with Heart Failure Quality of Life scale score through Day 180, and 90 day major adverse cardiac events. Additional secondary endpoints include change in dyspnea via visual analogue scale (VAS) and Likert 7-point comparator scale, N terminal pro-B-type natriuretic peptide value and New York Heart Association functional class, and the total amount of diuretics for the indexed AHF hospitalization. Study recruitment is expected to be completed by March 2021, and follow-up will end in September 2021. In an optional sub-study, patients will be followed up for 3 years.

Conclusions To our best knowledge, AUGUST-AHF is the first study assessing the efficacy of a Chinese herbal injection in patients with AHF. The results will be valuable to guide clinicians in using YiqiFumai lyophilized injection, which was included in the latest Chinese Health Insurance Catalog.

Keywords Acute heart failure; YiqiFumai lyophilized injection; Mortality; Readmission; Chinese medicine injection

Introduction

Heart failure (HF) is a group of complex clinical symptoms caused by abnormal changes in cardiac structure and/or function, resulting in abnormal ventricular systolic contraction and/or diastolic relaxation. Acute HF (AHF) refers to the rapid onset or deterioration of symptoms and/or signs of HF. It is a life-threatening condition that requires urgent assessment and treatment, usually leading to emergent hospitalization, especially among people aged 65 or older. AHF can present as a first occurrence of HF or as acute decompensation of chronic HF, which is more common and accounts for about 70–80% of all AHF hospitalizations.¹⁻³ Patients admitted for AHF have a high risk of mortality and readmission, especially in the first 90 days post discharge. The re-hospitalization rate in patients with AHF in 3–6 months after discharge was 10% to 20%, and the mortality rate was 20–30% in the same period.⁴ More specifically, depending on presentations, the 1 year mortality rate of patients admitted with AHF was 28.1% in pulmonary oedema, 54.0% in cardiogenic shock, 27.2% in decompensated HF, 12.8% in hypertensive HF, 34.0% in right HF and 20.6% in HF complicated with acute coronary syndrome, or 8.8% with reduced ejection fraction (<40%), 7.6% with mid-range ejection fraction (40–50%), and 6.3% with preserved ejection fraction (>50%).⁵,⁶ At present, treatment of AHF mainly includes intravenous diuretics with adjunctive vasodilators and inotropes, when necessary. However, in the past decade, studies on AHF treated with
new treatments or drugs have failed to prove long-term mortality benefits.\textsuperscript{7,8}

*YiqiFumai* lyophilized injection is an injection form herbal medicine extraction processed by modern technology from the ancient formula *Shengmai* powder, which is mainly composed of *Panax ginseng*, *Ophiopogon japonicus*, and *Schisandra chinensis*. Some studies have shown that *YiqiFumai* lyophilized injection can protect the myocardium by inhibiting oxidative injury, improving vascular endothelial function, and maintaining the functional integrity of myocardial tissue.\textsuperscript{9,10} At a molecular level, *YiqiFumai* lyophilized injection can inhibit mitogen-activated protein kinase, nuclear factor kappa-B, and other signal pathways and thus reduce the inflammation of myocardium, myocardial fibrosis, and ligation-induced ventricular remodelling, leading to improved cardiac function\textsuperscript{11–14} (Figure 1).

In China, *YiqiFumai* lyophilized injection is mainly used in the treatment of cardiovascular diseases including AHF. It was recently included in China’s new National Medical Insurance Catalog,\textsuperscript{15} although evidence supporting its use for such conditions including AHF is largely indeterminate owing to the poor quality of previous studies.\textsuperscript{16}

The objective of this study is to assess the effect of *YiqiFumai* lyophilized injection on the 90 day death or readmission rate in patients with AHF.

**Study design**

This multicentre, double-blind, randomized, placebo-controlled trial will be conducted at 50 hospitals in China. The study flow chart is presented in Figure 2. Study recruitment is expected to be completed by March 2021, and follow-up will end in September 2021. The trial was registered on www.Chictr.org.cn: ChiCTR2000029117.

The AUGUST-AHF Executive Committee (Appendix) designed the trial in collaboration with the corresponding author of this article. The trial is being conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. Written approval from the appropriate ethics committees is required, and each patient must provide written informed consent prior to participation.

**Study population**

To participate in AUGUST-AHF, patients must be \( \geq 18 \) years of age, fulfilling the 2017 American College of Cardiology Foundation/American Heart Association (ACC/AHA) guidelines\textsuperscript{2} for the diagnosis of AHF regardless of left ventricular ejection fraction or New York Heart Association

---

**Figure 1** Potential mechanisms of the beneficial effects of *YiqiFumai* lyophilized injection in patients with acute heart failure. ECM, extracellular matrix; IL, interleukin; CK, creatine kinase; LDH, lactate dehydrogenase; MAPKs, mitogen-activated protein kinases; MMPs, matrix metalloproteinases; NF-\( \kappa \)B, nuclear factor kappa-B; TIMPs, tissue inhibitor of matrix metalloproteinases; TNF-\( \alpha \), tumour necrosis factor-\( \alpha \).
functional class. Eligible patients are randomized within 16 h after presentation to the hospital into the two study arms. Detailed inclusion and exclusion criteria are listed in Table 1.

Table 1  Key inclusion and exclusion criteria in AUGUST-AHF

| Key inclusion criteria | Key exclusion criteria |
|-----------------------|------------------------|
| 1. Diagnosis of AHF   | 1. SPB ≤ 90 mmHg during baseline screening; patients who are known to be non-compliant, or those with uncontrolled hypertension (SBP ≥ 180 mmHg or DBP > 110 mmHg after treatment) |
| 2. Age ≥ 18 years     | 2. Haematocrit < 25% prior to enrolment, haemoglobin < 8.0 g/dL, or a history of transfusion within 14 days prior to screening, or active life-threatening gastrointestinal bleed |
| 3. Voluntarily participate in and sign the informed consent form | 3. Major neurological events, including cerebrovascular events, occurred within 60 days prior to enrolment |
| 4. Randomization will have to be completed within 16 h of presentation* | 4. Known liver damage or potentially severe liver disease (ALT or AST > 10 times normal) |
| 5. Known severe renal insufficiency (eGFR < 25 mL/min/1.73 m²) or planned or under dialysis, or apparent acute contrast nephropathy during screening period | 5. Known severe renal insufficiency (eGFR < 25 mL/min/1.73 m²) or planned or under dialysis, or apparent acute contrast nephropathy during screening period |
| 6. AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with ventricular rate < 45 b.p.m., or atrial fibrillation/flutter with sustained ventricular response of > 120 b.p.m. | 6. AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with ventricular rate < 45 b.p.m., or atrial fibrillation/flutter with sustained ventricular response of > 120 b.p.m. |
| 7. Known to have acute myocarditis, obstructive hypertrophic cardiomyopathy, complex congenital heart disease, constrictive or restrictive pericarditis, cardiac tamponade, severe aortic stenosis, or severe mitral stenosis | 7. Known to have acute myocarditis, obstructive hypertrophic cardiomyopathy, complex congenital heart disease, constrictive or restrictive pericarditis, cardiac tamponade, severe aortic stenosis, or severe mitral stenosis |
| 8. Severe aortic regurgitation or mitral regurgitation requiring surgery or percutaneous intervention | 8. Severe aortic regurgitation or mitral regurgitation requiring surgery or percutaneous intervention |
| 9. Dyspnoea due to obvious non-cardiac causes, such as acute or chronic respiratory disease or infection | 9. Dyspnoea due to obvious non-cardiac causes, such as acute or chronic respiratory disease or infection |
| 10. Patients who have received any organ transplant or is currently on the list to receive an organ transplant | 10. Patients who have received any organ transplant or is currently on the list to receive an organ transplant |
| 11. Current mechanical ventilation or circulation support (including within 2 h prior to screening) or planned to provide mechanical ventilation or circulation support (tracheal intubation, mechanical ventilation; intra-aortic balloon pump or any ventricular assist device; haemofiltration or dialysis) | 11. Current mechanical ventilation or circulation support (including within 2 h prior to screening) or planned to provide mechanical ventilation or circulation support (tracheal intubation, mechanical ventilation; intra-aortic balloon pump or any ventricular assist device; haemofiltration or dialysis) |
| 12. Those who have used the study medication 3 months before screening, or who have participated in other studies within 30 days before enrolment | 12. Those who have used the study medication 3 months before screening, or who have participated in other studies within 30 days before enrolment |
| 13. Pregnant or lactating women or those who want to become pregnant during the trial or within 3 months after treatment | 13. Pregnant or lactating women or those who want to become pregnant during the trial or within 3 months after treatment |
| 14. Patients with a history of YiqiFumai lyophilized injection allergy | 14. Patients with a history of YiqiFumai lyophilized injection allergy |
| 15. Patients with major psychiatric disorders, including but not limited to major depression, alcohol dependent; patients with a history of drug abuse, and those with active sexually transmitted infections (syphilis, genital warts, etc.) | 15. Patients with major psychiatric disorders, including but not limited to major depression, alcohol dependent; patients with a history of drug abuse, and those with active sexually transmitted infections (syphilis, genital warts, etc.) |
| 16. Patients with a history of any organ malignancy with or without treatment in the past year, or with a cancer diagnosis with known estimated life expectancy of < 1 year | 16. Patients with a history of any organ malignancy with or without treatment in the past year, or with a cancer diagnosis with known estimated life expectancy of < 1 year |
| 17. Those who are unable to follow the doctor’s advice or complete follow-up assessments or unsuitable for the trial as judged by the researchers at baseline assessment | 17. Those who are unable to follow the doctor’s advice or complete follow-up assessments or unsuitable for the trial as judged by the researchers at baseline assessment |

*Presentation starts as the earliest of time of presentation at the emergency room/department, intensive/cardiac care unit, or ward (excludes emergency medical service or other pre-hospital care).
clinical trials. The study is double-blinded. Independent drug administrators will log into the randomization system to obtain the group information with the random number, and then they will assign the research drug to the nurse who will be responsible for drug infusion. Opaque infusion bags together with infusion devices for both groups will be visually inspected by the hospital pharmacist to ensure identical appearances. Participants and all members of the study including the whole health care team are blinded to study drug assignment.

**Study intervention**

YiqiFumai lyophilized injection or placebo is administered as an intravenous infusion beginning within 4 h after randomization, ideally for 10 days. It has to be pointed out that unlike many developed countries, the length of stay for AHF hospitalizations is currently around 10 days in China. Patients in the treatment group will receive YiqiFumai lyophilized injection (eight bottles at once, 0.65 g/bottle, 5.2 g in total) diluted with 5% glucose or 0.9% normal saline injection, 250 mL once daily, at 40 drops per minute or 160 mL/h. The placebo group will receive 5% glucose or 0.9% normal saline injection 250 mL daily at the same infusion rate. Because patients with AHF are usually fluid overloaded, all patients will be monitored closely for tolerance during and after fluid infusions. Adverse events including worsening of symptoms will be documented and are allowed to justify the premature cessation of treatment or initiation of additional interventions if needed. Additionally, the steering committee (Appendix) of AUGUST-AHF will assess these adverse events.

**Table 2 Assessments schedule**

| Time points   | Screen | Baseline | Study drug infusion (10 days) | Follow-up |
|---------------|--------|----------|------------------------------|-----------|
|               | 16 h   | D0       | 24 h                         | D30       |
| Screening procedures | X      |          |                             |           |
| Basic information |        | X        |                              |           |
| Physical examination with vital signs |        | X        |                              |           |
| Body weight |        | X        |                              |           |
| Laboratory inspection |        | X        |                              |           |
| ECG |        | X        |                              |           |
| Myocardial injury biomarker |        | X        |                              |           |
| BNP/NT-proBNP |        |          |                              |           |
| NT-proBNP |        |          |                              |           |
| NYHA cardiac function classification |        |          |                              |           |
| Echocardiogram |        | X        |                              |           |
| HF signs and symptoms symptoms |        | X        |                              |           |
| Total intravenous diuretics |        | X        |                              |           |
| MLHFQ scale |        | X        |                              |           |
| Hospitalization days |        |          |                              |           |
| Assessment of readmission |        | X        |                              |           |
| Assessment of death |        | X        |                              |           |
| Major adverse cardiac events |        | X        |                              |           |
| Adverse and serious adverse events |        | X        |                              |           |
| Concomitant medication |        | X        |                              |           |

BPN, brain natriuretic peptide; ECG, electrocardiogram; HF, heart failure; MLHFQ, Minnesota Living with Heart Failure Quality of Life; NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; WHF, worsening heart failure; X, assessment.

**A** basic information include patient’s demographic information, disease history, alcohol and tobacco history, allergy history, and influenza vaccine history.

**B** laboratory examination include biochemistry, haematology, urine routine, will be measured locally at baseline and Day 10.

**E** CCGs will be performed and interpreted locally at screening and at Day 10 or discharge, whichever occurs first.

**M** yocardial injury biomarkers include creatine kinase isoenzyme, lactate dehydrogenase (LDH), and troponin, which will be measured locally at baseline.

**P** atients will be tested for BNP or NT-proBNP locally during screening.

**3** hundred patients will be selected for NT-proBNP testing at Day 10.

**H** HF signs and symptoms, and WHF are assessed through Day 10; and visual analogue scale is used to measure the dyspnoea at baseline, 6 h, 12 h, 24 h, and approximately the same time daily while hospitalized up to Day 10. Likert 7-point comparator scale is used for patients to compare the difference of his/her dyspnoea from the time of presentation to the hospital; the record time is the same as the visual analogue scale (VAS) except for the baseline.

The hospitalization days and coronary care unit (CCU) hospitalization days were recorded when the patients were discharged.

**M**ajor adverse cardiac events (MACEs), which were defined as the composite of total death; MI; stroke, hospitalization because of HF; and revascularization, including percutaneous coronary intervention, and coronary artery bypass graft.

**N** on-serious and serious adverse events will be reported from the signing of the informed consent form through Days 10 and 180, respectively.

**C** oncomitant medication will be recorded at baseline and during hospitalization and follow-up period. In the follow-up phase, only those drugs currently being taken or that were taken within 24 h prior to the visit (Day 30, Day 60, Day 90, and Day 180) will be collected.

**ESC Heart Failure 2020; 7: 3124–3133**

DOI: 10.1002/ehf2.12787
events throughout the trial and in case of an unexpectedly high event rate including premature cessation of fluid infusion may decide to unblind, pause, or stop the trial at any time, if deemed necessary. All patients will receive standard HF management during both the index hospitalization and the follow-up period for 180 days.

**Study assessments**

Patients will be assessed daily while hospitalized through Day 10. They will also be assessed at Days 30, 60, 90, and 180 (Table 2). At each of these assessment time point, HF signs and symptoms will be assessed and documented in the case report form, for example, dyspnoea evaluation via the visual analogue scale and the Likert 7-point comparator scale. Body weight is assessed through Day 10. Throughout this trial, especially during and right after study infusions, patients will be monitored closely for the occurrence of worsening HF, which is defined as worsening signs and/or symptoms of HF that require additional interventions, which may include increase in supplemental oxygen requirement, kidney or circulatory support, and mechanical ventilation. The daily total amount of diuretics, including intravenous and oral, will be recorded. Electrocardiograms and laboratory evaluation will be performed at baseline and Day 10 and as needed. N terminal pro-B-type natriuretic peptide will be checked in 300 patients at the selected sites at baseline and Day 10. The length of stay in the intensive care unit, if any, together with the length of stay in hospital will be recorded in the case report form. If patient is discharged prior to Day 10, necessary outcome lab tests and exams will be performed right before patient discharge. Patients will be observed 180 days after indexed hospital presentation for death, AHF rehospitalization, and major adverse cardiac events, which were defined as the composite of total death, myocardial infarction, stroke, hospitalization because of AHF, and revascularization, including percutaneous coronary intervention and coronary artery bypass graft. Additionally, non-serious adverse events are reported through Day 10 or discharge, and serious adverse events are reported through Day 180. All medication use will be recorded until the end of the last assessment time point. In a further optional sub-study, patients will be followed up remotely for between 3 years or till death.

In the follow-up period, we will use a smartphone-based application (app) to improve patient compliance. The physician will fill in the necessary details of post-discharge instructions and follow-ups in the app before patient discharge. Within 7 days prior to each visit point (Days 30, 60, 90, and 180), the app will request inputs from patients regarding medication and lifestyle modification compliance together with information for the Morisky Medication Adherence Scale (MMAS)-8, the Chinese version of which was found to have a relatively high reliability and validity for patients with HF.20

**Sample size calculation**

A sample size of 1270 participants will provide the trial with 80% power for the log-rank test to detect about 34% lower relative risk of 90 day all-cause mortality or readmission rate in the treatment group than in the placebo group with a two-sided significance level of 0.05 and 20% dropouts, assuming that a 90 day event rate of 20% for death or readmission in the placebo group on the basis of previous studies.21–23

**Statistical analysis**

For the primary outcome, the time from randomization to the first AHF readmission or all-cause death will be calculated in days through Day 90. Patients who withdraw consent or who are lost to follow-up without an event will be censored at the last date the patient was known to be alive. Kaplan–Meier estimates will be used, and the groups will be compared with a log-rank test. Relative risk reductions and

**Table 3 Outcomes**

| Outcomes                                      |
|-----------------------------------------------|
| **Primary outcome**                           |
| 1. 180 day all-cause mortality or heart failure readmission rate |
| 2. 90 day cardiac-specific mortality rate      |
| 3. Length of hospital stay for the indexed acute heart failure event |
| 4. 90 day major cardiovascular adverse event (MACE) incidence |
| 5. Occurrence of worsening heart failure (WHF) conditions through Day 10 |
| 6. Changes in Minnesota Living with Heart Failure Quality of Life (MLHFO) scale through Day 180 |
| 7. Total amount of intravenous diuretics for the indexed acute heart failure |
| 8. Change in dyspnoea via visual analogue scale (VAS) |
| 9. Change in dyspnoea via Likert 7-point comparator scale |
| 10. Change in NT-proBNP value                  |
| 11. Change in NYHA functional class            |

| **Secondary outcomes**                        |
|-----------------------------------------------|
| 1. 90 day all-cause mortality or heart failure readmission rate |
| 2. 90 day cardiac-specific mortality rate      |
| 3. Length of hospital stay for the indexed acute heart failure event |
| 4. 90 day major cardiovascular adverse event (MACE) incidence |
| 5. Occurrence of worsening heart failure (WHF) conditions through Day 10 |
| 6. Changes in Minnesota Living with Heart Failure Quality of Life (MLHFO) scale through Day 180 |
| 7. Total amount of intravenous diuretics for the indexed acute heart failure |
| 8. Change in dyspnoea via visual analogue scale (VAS) |
| 9. Change in dyspnoea via Likert 7-point comparator scale |
| 10. Change in NT-proBNP value                  |
| 11. Change in NYHA functional class            |

Major adverse cardiac events (MACE)s, which were defined as the composite of total death; MI; stroke, hospitalization because of HF; and revascularization, including percutaneous coronary intervention, and coronary artery bypass graft. NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.

**Study outcomes**

The primary endpoint is a composite of 90 day all-cause mortality or AHF readmission rate. The secondary endpoints are shown in Table 3. Adverse events, serious adverse events, and laboratory abnormalities will be recorded and compared between the two groups. All potential study endpoints will be adjudicated by a central adjudication committee (Appendix).
associated 95% confidence intervals (CIs) will be estimated from the Cox proportional hazards model including the group variable.

For the secondary outcomes, time-to-event variables will be analysed using the same analysis described for the primary outcome. Continuous variables will be assessed using the t-test or the Wilcoxon rank sum test as appropriate. Categorical variables will be compared between groups with the \( \chi^2 \) test or Fisher exact test. Longitudinal continuous variables will be analysed by fitting a repeated-measures analysis model. Additionally, adverse events, serious adverse events, and laboratory abnormalities will also be compared using the \( \chi^2 \) test or Fisher exact test, as appropriate.

All statistical analyses will be performed according to the intention-to-treat principle, using SAS version 9.4 (SAS Institute Inc) with a two-sided \( P \) value < 0.05 considered significant.

**Discussion**

In the past 20 years, with the application of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, cardiac resynchronization therapy, and implantable cardiac defibrillators, substantial progress has been made in the treatment of chronic HF, especially in decreasing the mortality rates in patients with HF with reduced ejection fraction. However, the available acute interventions in AHF have been largely limited to diuretics with uncertain long-term benefits from adjunctive vasodilators and inotropes. Despite therapeutic advances for chronic HF, AHF has high mortality and readmission rates, especially in the first 90 days post discharge. Treatments that may provide long-term mortality benefits and decrease hospital readmissions in patients with AHF remain highly sought after.

**Drug rationale**

*YiqiFumai* lyophilized injection, a contemporary Chinese herbal medicine preparation, is mainly used for the treatment of cardiovascular diseases in China. In animal models, *YiqiFumai* lyophilized injection was found to increase left ventricular contraction, reduce left ventricular end-diastolic pressure, and thus increase cardiac output. At a pathophysiological level, *YiqiFumai* lyophilized injection improves coronary blood flow, reduces myocardial oxygen consumption, inhibits inflammatory mediators, and reduces myocardial injury.\(^{12,13,24}\) It also has been found to improve extracellular matrix remodelling by inhibiting the activity of myocardial matrix metalloproteinases.\(^{24}\) In a meta-analysis that included a total of 20 randomized controlled trials, Xie and Dai\(^{16}\) reported that on top of an acceptable safety profile, *YiqiFumai* lyophilized injection when combined with standard HF therapy may improve the performance of 6 min walk test and cardiac function via increasing left ventricular ejection fraction and reducing left ventricular end-diastolic dimension.

The dose used in the drug manual per the manufacturer is 5.2 g (eight bottles) once daily; it is also the dosage used in most previous clinical studies.\(^{16}\) In our trial, we will utilize the same dosing regimen. The dripping rate will be about 40 drops per minute or 160 mL/h as recommended in the instructions. The majority of the previous studies adopted a 7 or 10 day course of treatment and reached statistically significant clinical benefits as compared with control; as a result, the duration of treatment in this trial aims at maximal 10 days unless that the patient is discharged prior to that.

**Population rationale**

For patient recruitment, there is no limitation on left ventricular ejection fraction in patients with AHF in this trial. Rationales include the following: (i) potential variations in clinical effects of *YiqiFumai* lyophilized injection remain unclear in patients with different left ventricular ejection fraction, and (ii) restriction on patient selection will limit the applicability of the intervention in the AHF population. Included patients’ plasma natriuretic peptide levels will be in line with the diagnostic criteria of the 2017 ACC/AHA guidelines for AHF.\(^2\)

**Assessment time point rationale**

There are two important time points in our trial: 90 days and 16 h. The former indicates that the primary outcome evaluation time point is 90 days after hospital presentation. The early stage after hospitalization of AHF, also known as ‘the vulnerable stage’, has a particularly high risk for adverse clinical outcomes; it is the period when most cardiovascular events occur. The exact time when the vulnerable period extends to is not clear, but limited evidence shows that it can last as long as 60–90 days.\(^{25,26}\) As a result, many studies use 90 days as one of the cut point for outcome assessments in patients with AHF. Similarly, we utilize 90 days after initial evaluation as the major outcome assessment time point for this trial, assessing the efficacy of *YiqiFumai* lyophilized injection in AHF.

In this trial, eligible patients are randomized within 16 h after hospital presentation. Patients were randomized within 48 h of hospitalization in the ASCEND-HF trial and within 16 h from presentation in the RELAX-AHF trial; the results from these trials revealed that the actual median time elapsed till receiving treatment was 15.5 and 7.9 h, respectively.\(^{23,27}\) Although neither ASCEND-HF nor RELAX-AHF demonstrated benefits of the studied medication
in cardiovascular death or hospital readmission for HF, the RELAX-AHF trial did find that serelaxin (30 μg/kg per day) was associated with dyspnoea relief and decreased deaths at Day 180.23 On the other hand, nesiritide was not associated with the rate of death, and its effects on dyspnoea were small and nonsignificant in the ASCEND-HF trial.27

Early intervention may play a role in the positive benefits of serelaxin in the RELAX-AHF trial. Does it mean the sooner the better? Not really. One study showed that only two-thirds of patients suspected of AHF within 1 h of presentation were finally confirmed to have AHF at 6 h after presentation, suggesting that an early intervention for susceptible AHF may lead to inclusions of patients with a false diagnosis of AHF.28 No information was provided in previous studies on the timing of initiating YiqiFumai lyophilized injection for AHF,16 and the effects of early versus late initiation of YiqiFumai lyophilized injection for the treatment of AHF remain to be explored. Taking into consideration all the available information, we chose 16 h after hospital presentation to maximize the potential benefits of YiqiFumai lyophilized injection while also providing reasonable time frame for the correct diagnosis of AHF.

### Study design rationale

In this trial, we use opaque dark colour infusion bags and for the double-blind design because the mixture injection solution with herbal extracts has a distinct colour, and blinding can be difficult without similar appearances.29 This is also the possible reason that most previous herbal injection clinical trials were not double-blind. Our design thus can minimize selection and evaluation bias caused by unblinding, providing fair, objective, and reliable results.

During the follow-up period of this trial, the highlight is that we designed a smartphone app to improve patient compliance. Patients will enter a follow-up period after discharge from the hospital till Day 180. Patient compliance is known to be very important in the management of HF.1–3 Patients should follow physicians’ instructions after hospital discharge,

### Table 4 Comparison of AUGUST-AHF and ACT-ADIHF designs

|                      | AUGUST-AHF                          | ACT-ADIHF                       |
|----------------------|-------------------------------------|---------------------------------|
| **Design**           | Multicentre                         | Multicentre                     |
| **Sample size**      | 1270 (ongoing)                      | 666 (ongoing)                   |
| **Random method**    | IWRS                               | IWRS                            |
| **Blind method**     | Double blind                        | Single blind                    |
| **Inclusion criteria** |                                   |                                 |
| **Population**       | Acute HF                            | Acute decompensated ischaemic HF |
| **Age**              | ≥18 years                           | 40–79 years                     |
| **Randomized time**  | Within 16 h of presentation         | Unclear                         |
| **Diagnosed with coronary heart disease** | No                                  | Yes                             |
| **NYHA classification** | No limitation                      | III~IV                           |
| BNP/NT-proBNP        | No limitation                       | BNP > 200 pg/mL                 |
| LVEF                 | No limitation                       | No limitation                   |
| **Intervention**     | YiqiFumai lyophilized injection + standardized western medications | YiqiFumai lyophilized injection + standardized western medications |
| **Treatment group**  | Placebo (5% glucose or 0.9% normal saline injection 250 mL) + standardized western medications | Standardized western medications |
| **Control group**    | Placebo (5% glucose or 0.9% normal saline injection 250 mL) | Placebo (5% glucose or 0.9% normal saline injection 250 mL) |
| **Administration time of study drug** | No more than 4 h after randomization | No more than 4 h after randomization |
| **Intervention phase** | 10 days                            | 7 days                          |
| **Follow-up phase**  | 180 days                            | 60 days                         |
| **Ways to improve compliance** | Customized follow-up APP | Unclear                         |
| **No. of visits planned** | 18                                 | 4                              |
| **Outcomes**         |                                     |                                 |
| **Primary outcome**  | 90 day all-cause mortality or HF readmission | BNP level Composite endpoint (all-cause death, HF emergency/readmission, acute coronary syndrome, revascularization, malignant arrhythmia, cardiogenic shock, stroke, and pulmonary embolism), LVEF, TNT/TNI, cardiothoracic ratio, life quality scale, scores of the four TCM diagnostic methods |
| **Secondary outcomes** | 180 day all-cause mortality or HF readmission rate, length of hospital stay, 90 day cardiovascular death rate, 90 day MACE incidence, WHF through Day 10, MLHFO scale, dyspnoea VAS score, Likert 7-point comparator scale, NYHA functional class, total amount of intravenous diuretics, NT-proBNP |

BNP, brain natriuretic peptide; HF, heart failure; IWRS, interactive web response system; LVEF, left ventricle ejection fraction; MACE, major cardiovascular adverse event; MLHFO, Minnesota Living with Heart Failure Quality of Life; NT-proBNP, N terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; TCM, traditional Chinese medicine TNT/TNI, troponin T/I; VAS, visual analogue scale; WHF, worsening heart failure.
including medication compliance, lifestyle modification, diet, and exercises. Patients’ non-compliance with physician instructions can result in worsening HF symptoms, leading to re-hospitalizations or even more serious cardiovascular events. Nowadays, the increase in the complexity of treatment plans for HF has further reduced the compliance of patients, especially in elderly people. In HF trials, patients’ compliance during the follow-up period likely also plays a role in the credibility of trial results. To address this problem, we designed a smartphone-based app to improve patient adherence. This app mainly reminds patients to fill in the data regarding treatments and the MMAS-8 within 7 days prior to each assessment time points (Day 30, Day 60, Day 90, and Day 180).

Primary outcome rationale

We selected the primary outcome as the composite endpoint of 90 day all-cause mortality or HF readmission rate for the following three reasons. Firstly, reducing mortality and re-hospitalization rates of HF are a goal of important clinical significance for patients, physicians, and health policy decision makers. The 2018 Chinese HF guidelines clearly advocate that clinical studies of Chinese herbal therapies should emphasize and include their mortality impacts as the primary endpoint. Secondly, the composite endpoints may improve trial efficiency by increasing the event incidence rate and reducing the required sample size and allowing adequate accrual of events over a shorter follow-up period. Thirdly, in previous clinical studies on *YiqiFumai* lyophilized injection, the mortality and readmission rates were not primary endpoints. For example, the trial of ACT-ADIHF published in 2018 assessed the efficacy of *YiqiFumai* lyophilized injection on acute decompensated ischaemic HF; the primary outcome of this trial was the change in BNP concentrations. As the ACT-ADIHF is the only relatively well-designed trial for *YiqiFumai* lyophilized injection so far, we compared the differences in the study design between this trial and the ACT-ADIHF trial (Table 4).

Conclusion

To our best knowledge, AUGUST-AHF is the first multicentre, large sample, randomized, double-blind, placebo-controlled trial to assess the efficacy of a Chinese herbal medicine injection for patients with AHF. The results will be valuable to answer the question regarding the efficacy of this medication and guide clinicians in using *YiqiFumai* lyophilized injection, which was included in the latest National Medical Insurance Catalog of China.

Conflict of interest

None declared.

Author Contributions

Hongcai Shang and Yan Liu drew up the research design. Jingjing Zhang and Yang Sun drafted the protocol. Jingjing Zhang, Kehua Zhou, and Yan Liu wrote the manuscript in English. Ying Chen, Jiayuan Hu, and Changming Zhong participated in the design amendment and helped with the project coordination. Hongcai Shang, Yan Liu, Xiaoyu Zhang, and Ying Chen contributed to protocol ethics and trial registration. Kehua Zhou revised the details and the language. Yan Liu made the statistical plan. Hongcai Shang is the principal investigators of the whole project. All authors reviewed the manuscript content and approved the final version for submission.

Funding

This work was supported by the National Key Research and Development Plan (2017YFC1700400 and 2017YFC1700403).

Appendix

Executive Committee: Keji Chen, Yun Zhang, Jian Zhang, Zhaoxiang Bian, Wei Wang.
Data and Safety Monitoring Committee: Xin Sun, Zhangsheng Yu, Xiaohua Zhou, Hao Xu, Xinfeng Guo.
Endpoint Adjudication Committee: Keji Chen, Yunlong Xia, Hongxu Liu, Mingjun Zhu, Jian Zhang.

References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; 2016: 891–975.

2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Dzavner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol* 2017; 70: 776–803.

3. Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2018. *Chinese Journal of Cardiology* 2018; 46: 760–789.

4. Gheorghiade M, Pang PS. Acute heart failure syndromes. *J Am Coll Cardiol* 2009; 53: 557–573.

5. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced LVEF in China: the Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017; 19: 1242–1254.

6. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, Heart Failure Long-Term Registry Investigators ESC. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017; 19: 1242–1254.

7. Diez J, Ruilope LM. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. *Eur Heart J Cardiovasc Pharmacother* 2016; 2: 119–130.

8. Goldsmith SR. A new approach to treat myocardial oxidative damage in mice. *J Pharmacol Sci* 2013; 122: 17–27.

9. Li F, Tan Y, Chen H, Yan Y, Zhai K, Li D, Kou J, Yu B. Identification of schisandrin as a vascular endothelium protective component in YiqiFumai Powder Injection using HUVECs binding and HPLC-DAD-Q-TOF-MS/MS analysis. *J Pharmacol Sci* 2015; 129: 1–8.

10. Xing L, Jiang M, Dong L, Gao J, Hou Y, Bai G, Luo G. Cardioprotective effects of the YiqiFumai injection and isolated compounds on attenuating chronic heart failure via NF-κB inactivation and cytokine suppression. *J Ethnopharmacol* 2013; 148: 239–245.

11. Zhang Q, Wang B, Liu W, Deng Y. Effects of YiqiFumai injection on cardiac function and heart failure markers in rats with chronic heart failure. *Liaoan Journal of Traditional Chinese Medicine* 2015; 42: 2233–2235.

12. Zhang Q, Wang B, Liu W, Deng Y. Regulatory effects of YiqiFumai injection on the activity of matrix metalloproteinase in rats with chronic heart failure. *Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease* 2016; 14: 825–829.

13. Pang L, Ju A, Zheng X, Li F, Song Y, Zhao Y, Guo Y, Chen F, Liu C, Qi J, Gao Z, Kou J, Yu B. YiqiFumai injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway. *J Ethnopharmacol* 2017; 202: 67–77.

14. National healthcare security administration. National Healthcare Security Administration. National Ministry of Human Resources and Social Security issued a list of drugs for access to national health insurance negotiations in 2019. [http://www.nhsa.gov.cn/module/download/file.jsp?classid=0&filename=e76869776214c60b2a67bc820bdcb.pdf](http://www.nhsa.gov.cn/module/download/file.jsp?classid=0&filename=e76869776214c60b2a67bc820bdcb.pdf) (28 November 2019).

15. Xie N, Dai X. Meta-analysis on curative effects of YiqiFumai injection (lyophilization) for heart failure. *Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease* 2019; 17: 1499–1503.

16. Hewitt CE, Torgerson DJ. Is restricted randomisation necessary? *BMJ* 2006; 332: 1506–1508.

17. Zhang Y, Zhang J, Butler J, Yang X, Xie P, Guo D, Wei T, Yu J, Wu Z, Gao Y, Han X, Zhang X, Wen S, Anker SD, Filippatos G, Fonarow GC, Gan TY, Zhang RC, Investigators C-HF. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart Failure (China-HF) Registry. *J Card Fail* 2017; 23: 868–875.

18. Li L, Liu R, Jiang C, Du X, Huffman MD, Lam CS, Patel A, Hills GS, Anderson CS, Ma C, Zhao X, Wang X, Li L, Dong J. Assessing the evidence-predictive role for heart failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. *Eur J Heart Fail* 2019, in press; 22: 646–660.

19. Chen Q, Qu S, Huang X. Analysis and practice of reliability and validity evaluation of medication compliance in patients with chronic cardiovascular disease by Chinese version of MMAS-8. *China Pharmacy* 2019; 30: 268–271.

20. Konstan MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. *JAMA* 2007; 297: 1319–1331.

21. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelweicz CH, Jaumont X, Lesogor A, Maggioni AP, ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. *JAMA* 2013; 309: 1125–1135.

22. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF, Gorodnati MI, Grinfeld LR, Jordeau G, Marmer A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M. RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. *Lancet* 2013; 381: 29–39.

23. Ju A, Luo R, Qin X, Su X, Li D, Zhou D, Ye Z. Pharmacological effects and clinical research progress of YiqiFumai lyophilized injection. *Drug Evaluation Research* 2018; 41: 231–234.

24. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. *Nat Rev Cardiol* 2015; 12: 220–229.

25. Vaduganathan M, Patel RB, Greene SJ, Gheorghiade M. Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. *Eur J Heart Fail* 2016; 18: 1190–1192.

26. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizger GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Claessens N, Corbalan R, Costanzo MR, Dahlstrom U, Deedwania P, Diab I, Dunlap RJ, Ezekovitz JA, Felder GM, Fonarow GC, Gennevossis D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal...
S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Wilson WH, Tanomsup S, Teerlink JR, Tripodiakis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med* 2011; 365: 32–43.

28. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Courtney D, Hasa J, Spinar J, Masip J, Frank Peacock W, Sliva K, Gayat EFG, Cleland JG, Gheorghiade M. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. *Eur Heart J* 2010; 31: 832–841.

29. Food S, Administration D. National Drug Standards (amendment) promulgated pieces. *Drug Stand China* 2013; 14: 448–473.

30. Van der Wal MH, Jaarsma T, van Veldhuisen DJ. Non-compliance in patients with heart failure; how can we manage it? *Eur J Heart Fail* 2005; 7: 5–17.

31. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrl H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. *Eur J Heart Fail* 2013; 15: 1082–1094.

32. Anker SD, Schroeder S, Atar D, Bax JJ, Cecconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, LeFloh C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. *Eur J Heart Fail* 2016; 18: 482–489.

33. Wang X, Zhao Z, Hou Y, Tang E, Zhao G, Wang S, Bi Y, Zhong C, Ren M, Zhang J, Mao J, Zhang B. Assessment of Complementary Treatment with YiqiFumai Lyophilized Injection on Acute Decompensated Ischemic Heart Failure (ACT-ADIHF): Rationale and design of a multicenter, randomized, controlled trial. *Cardiovasc Drugs Ther* 2018; 32: 295–300.